Business
CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has rescheduled its previously announced fourth quarter and full year 2024 earnings call to allow more time to complete the annual financial audit prior to the earnings release.
About this update from Cytosorbents Corporation
[{"type":"text","content":"The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing applications in 2025","length":219,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., March 21, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has rescheduled its previously announced fourth quarter and full year 2024 earnings call to allow more time to complete the annual financial audit prior to the earnings release.","length":425,"tagName":"p"},{"type":"image","alt":"CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents’ flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approval of DrugSorb™-ATR for antithrombotic drug removal during cardiothoracic surgery. (PRNewsfoto/CytoSorbents Corporation)","displaySize":"","headline":null,"caption":"CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents’ flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approval of DrugSorb™-ATR for antithrombotic drug removal during cardiothoracic surgery. (PRNewsfoto/CytoSorbents Corporation)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":75,"url":"https://media.zenfs.com/en/prnewswire.com/9676107c0e6110f38248a9b901be667e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1AvWc9mJ5OQ7bf_iJlIFzQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9676107c0e6110f38248a9b901be667e","width":400,"height":75}},"href":"https://mma.prnewswire.com/media/2647016/CytoSorbents_Working_To_Save_Lives_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Company now expects to report fourth quarter and full year 2024 financial results and file its Form...